-+ 0.00%
-+ 0.00%
-+ 0.00%

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

Barchart·07/24/2026 05:15:00
Listen to the news

Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of neovascular age-related macular degeneration (nAMD).5 Susvimo is intended for continuous release into the vitreous using the Contivue implant.6 A final decision is expected from the European Commission in the near future.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.